![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Gallego Juan A Nielsen Jimmi De Hert Marc Kane John M Correll Christoph U
Publisher: Informa Healthcare
ISSN: 1474-0338
Source: Expert Opinion on Drug Safety, Vol.11, Iss.4, 2012-07, pp. : 527-542
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Current Pharmaceutical Design, Vol. 10, Iss. 18, 2004-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Antipsychotic polypharmacy in schizophrenia in Canada
Inpharma, Vol. 1, Iss. 1296, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Antipsychotic Polypharmacy in Schizophrenia: Benefits and Risks
By Barnes Thomas R.E. Paton Carol
CNS Drugs, Vol. 25, Iss. 5, 2011-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Antipsychotic polypharmacy determined by severity of psychosis
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 494, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Haematological safety of antipsychotic drugs
By Hall RL Smith AG Edwards J Guy
Expert Opinion on Drug Safety, Vol. 2, Iss. 4, 2003-07 ,pp. :